Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis

Qifeng Li, Baoshan Xu, Qifeng Li, Baoshan Xu

Abstract

Background: This meta-analysis was performed to assess the efficacy of risedronate in increasing bone mineral density (BMD) in patients undergoing primary total hip arthroplasty (THA).

Methods: We systematically searched the following databases: PubMed, Embase, Web of Science, Cochrane Library, and Chinese Wanfang database from inception up to October 2017. Included patients were prepared for THA and were separated into two groups: intervention group (risedronate treatment) and control group (placebo treatment). BMD change in Gruen zone 1 and 7 were primary outcomes. Meta-analysis was performed using Stata 12.0 software.

Results: Five randomized controlled trials (RCTs) involving 259 patients (risedronate group = 127, control group = 132) were finally included in this meta-analysis. Meta-analysis indicated that oral risedronate significantly increased the BMD change in Gruen zone 1. However, there was little clinical significance between the risedronate and control group in terms of the Gruen zones 2, 3, and 7. Oral risedronate significantly increased the Harris hip scores compared with the control group (P < 0.05).

Conclusion: Oral risedronate could significantly reduce peri-prosthetic bone resorption around an uncemented femoral stem (Gruen zone 1) after THA. Due to the limited included studies, more high-quality randomized controlled trials (RCTs) were still needed to identify the efficacy of risedronate for bone loss in THA.

Keywords: Meta-analysis; Risedronate; Total hip arthroplasty.

Conflict of interest statement

Ethics approval and consent to participate

None

Competing interests

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA flow chart of retrieved studies
Fig. 2
Fig. 2
Risk of bias summary
Fig. 3
Fig. 3
Risk of bias graph
Fig. 4
Fig. 4
Forest plot comparing the BMD change in zone 1 between the two groups
Fig. 5
Fig. 5
Forest plot comparing the BMD change in zone 7 between the two groups
Fig. 6
Fig. 6
Forest plot comparing the BMD change in zone 2 between the two groups
Fig. 7
Fig. 7
Forest plot comparing the BMD change in zone 3 between the two groups
Fig. 8
Fig. 8
Forest plot comparing the BMD change in zone 4 between the two groups
Fig. 9
Fig. 9
Forest plot comparing the BMD change in zone 5 between the two groups
Fig. 10
Fig. 10
Forest plot comparing the BMD change in zone 6 between the two groups
Fig. 11
Fig. 11
Forest plot comparing the Harris hip scores between the two groups

References

    1. Zhao X, Hu D, Qin J, et al. Effect of bisphosphonates in preventing femoral periprosthetic bone resorption after primary cementless total hip arthroplasty: a meta-analysis. J Orthop Surg Res. 2015;10:65. doi: 10.1186/s13018-015-0206-8.
    1. Furnes O, Lie SA, Espehaug B, et al. Hip disease and the prognosis of total hip replacements. A review of 53,698 primary total hip replacements reported to the Norwegian arthroplasty register 1987-99. J Bone Joint Surg Br. 2001;83(4):579–586. doi: 10.1302/0301-620X.83B4.11223.
    1. Canales Cortes V, Panisello Sebastia JJ, Herrera Rodriguez A, et al. Ten-year follow-up of an anatomical hydroxyapatite-coated total hip prosthesis. Int Orthop. 2006;30(2):84–90. doi: 10.1007/s00264-005-0065-8.
    1. Gallo J, Landor I, Cechova I, et al. Comparison of hydroxyapatite-coated stems in total hip arthroplasty after a minimum 10-years follow-up. Acta Chir Orthop Traumatol Cechoslov. 2008;75(5):339–346.
    1. Lin T, Yan SG, Cai XZ, et al. Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials. Osteoporos Int. 2012;23(6):1823–1834. doi: 10.1007/s00198-011-1797-5.
    1. Prieto-Alhambra D, Javaid MK, Judge A, et al. Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study. BMJ. 2011;343:d7222. doi: 10.1136/bmj.d7222.
    1. Eskelinen A, Remes V, Helenius I, et al. Uncemented total hip arthroplasty for primary osteoarthritis in young patients: a mid-to long-term follow-up study from the Finnish Arthroplasty Register. Acta Orthop. 2006;77(1):57–70. doi: 10.1080/17453670610045704.
    1. Bhandari M, Bajammal S, Guyatt GH, et al. Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty. A meta-analysis. J Bone Joint Surg Am. 2005;87(2):293–301. doi: 10.2106/JBJS.D.01772.
    1. Kinov P, Tivchev P, Doukova P, et al. Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomised study. Acta Orthop Belg. 2006;72(1):44–50.
    1. Kumar N. The effect of weekly Risedronate on periprosthetic bone resorption following total hip arthroplasty. A randomized, double-blind, placebo-controlled trial. J Bone Joint Surg (Am Vol) 2011;93(20):1857. doi: 10.2106/JBJS.J.01646.
    1. Skoldenberg OG, Salemyr MO, Boden HS, et al. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial. J Bone Joint Surg Am. 2011;93(20):1857–1864. doi: 10.2106/JBJS.J.01646.
    1. Malouf-Sierra J, Tarantino U, Garcia-Hernandez PA, et al. Effect of teriparatide or risedronate in elderly patients with a recent Pertrochanteric hip fracture: final results of a 78-week randomized clinical trial. J Bone Miner Res. 2017;32(5):1040–1051. doi: 10.1002/jbmr.3067.
    1. Aspenberg P, Malouf J, Tarantino U, et al. Effects of teriparatide compared with risedronate on recovery after pertrochanteric hip fracture: results of a randomized, active-controlled, double-blind clinical trial at 26 weeks. J Bone Joint Surg Am. 2016;98(22):1868–1878. doi: 10.2106/JBJS.15.01217.
    1. Gruen TA, McNeice GM, Amstutz HC. “Modes of failure” of cemented stem-type femoral components: a radiographic analysis of loosening. Clin Orthop Relat Res. 1979;141:17–27.
    1. Muren O, Akbarian E, Salemyr M, et al. No effect of risedronate on femoral periprosthetic bone loss following total hip arthroplasty. A 4-year follow-up of 61 patients in a double-blind, randomized placebo-controlled trial. Acta Orthop. 2015;86(5):569–574. doi: 10.3109/17453674.2015.1041846.
    1. Yamasaki S, Masuhara K, Yamaguchi K, et al. Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. Osteoporos Int. 2007;18(7):1009–1015. doi: 10.1007/s00198-007-0339-7.
    1. Higgins JPT, Green S (editors). The Cochrane collaboration, 2011[J]. 2011. [updated March 2011], , Available: .
    1. Prieto-Alhambra D, Javaid MK, Judge A, et al. Fracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate use. Arthritis Rheum. 2011;63(4):992–1001. doi: 10.1002/art.30214.
    1. Eberhardt C, Habermann B, Muller S, et al. The bisphosphonate ibandronate accelerates osseointegration of hydroxyapatite-coated cementless implants in an animal model. J Orthop Sci. 2007;12(1):61–66. doi: 10.1007/s00776-006-1081-2.
    1. Friedl G, Radl R, Stihsen C, et al. The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. J Bone Joint Surg Am. 2009;91(2):274–281. doi: 10.2106/JBJS.G.01193.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir